Abstract
Introduction: Peripartum cardiomyopathy (PPCM) develops around the end of pregnancy or in the initial months after delivery. PPCM is induced by vasculotoxic chemicals secreted from the placenta and pituitary. Prolactin is one of these hormones that could be harmful. The maternal pituitary release prolactin in response to breastfeeding. The advantages of nursing for both mother and child must be taken seriously while deciding whether to breastfeed with PPCM. This systematic review aims to analyze the existing scientific evidence on breastfeeding in PPCM patients. Method: To ensure comprehensive retrieval of relevant research we search the following key databases: PubMed and ScienceDirect through 1000 for peer reviewed articles (in all languages) evidence related to breastfeeding in peripartum cardiomyopathy. Results: The studies suggest that PPCM influenced by the hormone prolactin which related to breastfeeding. Therapy of prolactin inhibitors is given to inhibit the worsening of PPCM patients, but with side effects patients cannot provide exclusive breastfeeding. From the study, breastfeeding has no significant effect on the LVEF of mothers with PPCM, but in PPCM conditions that are not well compensated, breastfeeding is not recommended and patients should undergo therapy with bromocriptine. Conclusion: Breastfeeding and bromocriptine go opposite but both have benefits for PPCM patients, consideration for breastfeeding or bromocriptine administration must considering the patient's condition. Administration of bromocriptine for certain conditions such as severe PPCM can accelerate LV function recovery. There will be side effects for both children and mothers who are not breastfed.
Published Version (
Free)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call